Clinical Trial Update: A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy [Phase 2]

View source ↗

Summary

A Phase 2 randomized, placebo-controlled trial evaluating daily BMS-275291 for 12 months in women with early-stage breast cancer receiving adjuvant therapy; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BMS-275291

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED